Costs and Outcomes of Use of Amitriptyline, Citalopram and Fluoxetine in Major Depression: Exploratory Study

Hosák, Ladislav; Tůma, Ivan; Hanuš, Herbert; Straka, Libor

doi:10.14712/18059694.2019.127

Acta Medica > Archive > 2000, Vol. 43 > Issue 4 > Costs and Outcomes of Use of…

Acta Med. 2000, 43: 133-136

https://doi.org/10.14712/18059694.2019.127

Costs and Outcomes of Use of Amitriptyline, Citalopram and Fluoxetine in Major Depression: Exploratory Study

Ladislav Hosák^a, Ivan Tůma^a, Herbert Hanuš^a, Libor Straka^b

^aCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Psychiatry, Hradec Králové, Czech Republic
^bCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Medical Biophysics, Hradec Králové, Czech Republic

Received June 1, 2000
Accepted October 1, 2000

Background: The increasing cost of pharmaceuticals in the Czech Republic has led to the restriction on prescriptions of expensive new antidepressants. The aim of the study was to compare the costs and outcomes of using amitriptyline, citalopram and fluoxetine in the treatment of major depression. Methods: Ninety patients (69 women) with a mean age of 44.5 years (S.D.=14.3) suffering from major depression were treated with amitriptyline (N=31), citalopram (N=29) and fluoxetine (N=30). Direct medical costs and effectiveness (indicated by the number of hospitalization-free days) were assessed in a prospective, open, intent-to-treat study. Results: Neither cost nor effectiveness were significantly different among the treatment groups. Conclusion: Amitriptyline treatment is not less expensive nor more effective than citalopram or fluoxetine therapies. There is no advantage in restricting patients from treatment with SSRIs, which have fewer adverse effects and a decreased risk of a lethal overdosage in comparison with tricyclic antidepressants.